As inferred by enrichment of PIK3CA somatic mutation, clear cell carcinomas demonstrated superior sensitivities to PAM pathway inhibitors, including BKM120 (PI3K, P = 1.88 × 10−03) and AZD2014 (mTOR, P = 2.25 × 10−03). This evidence concerns the gene PIK3CA and clear cell adenocarcinoma.